Heart failure after the trial decade: what 125 studies bought us

The ejection fraction number rules your appointments, the medication list is optimised to guideline perfection, and yet capacity keeps shrinking. Cardiac cell therapy once carried enormous expectations — billions in funding, hundreds of trials. You deserve the honest summary of what all that bought.

What the data says for this situation

Cardiology ran the field's biggest natural experiment: our snapshot still counts 32 MSC and 13 HSCT studies, 125 across all cell types for heart failure. Two decades of trials — bone-marrow cells post-infarct, MSCs in chronic failure — delivered a hard lesson: early small studies glowed, large controlled ones (the definitive multi-centre trials of the 2010s) showed marginal-to-no improvement in ejection fraction or survival. One notable recent large trial reported reduced cardiovascular events in an inflammation-marked subgroup — the field's remaining live thread. Nothing is approved, and the cardiology establishment has largely moved its regeneration hopes to other technologies.

Questions worth asking any provider

1. Which large controlled trial supports offering this to my HF class?
2. Inflammation-subgroup logic: does my profile actually match it?
3. How would this interact with my guideline therapy and devices?
4. Endpoint honesty: symptoms, imaging, or survival — what changed in the cited study?

Red flags specific to this situation

• Ejection-fraction improvement promises citing early-2000s pilot data
• Cell packages sold alongside “detox” cardiology
• No heart-failure cardiologist reviewing your case

Cost context

Cardiac infusion packages abroad run €12,000–€30,000 against a trial record that large studies read as neutral. The same money buys years of optimised guideline care adherence support.

FAQ

Did cardiac stem cell therapy fail?

The strong version did: large trials showed little functional benefit. A subgroup signal on inflammation keeps a narrower hypothesis alive.

Is anything approved for hearts?

No cell product is approved for heart failure by FDA or EMA.

→ Build questions for a specific provider · → Cost calculator

Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.